Celltrion (068270.KS)

Executive Summary

Celltrion is South Korea's premier biopharmaceutical company and the world's largest biosimilar manufacturer, with FDA and EMA cGMP-certified facilities boasting 250,000L production capacity. Its integrated one-stop solution spans R&D, clinical development, regulatory affairs, manufacturing, and global distribution across ~100 countries. The company's mission is to provide affordable, advanced biologics to improve patient health worldwide. With a strong commercial portfolio including Remsima (infliximab), Herzuma (trastuzumab), and Truxima (rituximab), Celltrion has established itself as a leader in the biosimilar market, capturing significant share in both developed and emerging markets. The company continues to expand its pipeline with biosimilars targeting blockbuster biologics such as aflibercept, omalizumab, and daratumumab, while also investing in novel antibody and biologic therapies. Supported by a robust financial position and a valuation of over $45 billion, Celltrion is well-positioned to sustain its growth trajectory and maintain its competitive edge as a global biosimilar powerhouse. The company's recent Phase 3 completions and ongoing trials underscore its commitment to bringing high-quality, cost-effective treatments to patients, and its direct distribution network enhances market access and profitability.

Upcoming Catalysts (preview)

• Q3 2026FDA Decision on CT-P42 (aflibercept biosimilar) for DME/wAMD85% success
• Q4 2026EU Approval Decision on CT-P39 (omalizumab biosimilar) for CSU80% success
• Q2 2027Interim Phase 3 Data Readout for CT-P44 (daratumumab biosimilar) in Multiple Myeloma70% success